A meta-analysis by Broglio et al. [17] including 36 randomized clinical trials (RTCs), including stage I-III HER2-positive breast cancer patients treated with NACT, showed a substantial improvement in event-free survival for pCR vs. non-pCR, with an HR of 0.37 (95% PI 0.32–0.43); this association was greater for patients with hormone-receptor-negative disease with an HR of 0.29 (95% PI 0.24–0.36) than for hormone-receptor-positive disease with an HR of 0.52 (95% PI 0.40–0.66). This evidence concerns the gene NR4A1 and breast cancer.